Form 4: Stryker Group President Receives Equity Grants
Executive Compensation Grant
Stryker's Group President, James Andrew Pierce, was granted 2,771 Restricted Stock Units and 15,300 employee stock options.
Summary
- James Andrew Pierce, Group President of Stryker Corp (SYK), received a grant of 2,771 Restricted Stock Units (RSUs) on February 4, 2026.
- Each RSU represents a contingent right to receive one share of Stryker Common Stock, with a grant price of $0.
- These RSUs will vest in three equal installments: one-third on March 21, 2027, one-third on March 21, 2028, and the final one-third on March 21, 2029.
- Pierce also received a grant of 15,300 employee stock options on February 4, 2026, with an exercise price of $360.82 per share.
- These stock options become exercisable as to 20% on each of the first five anniversaries of the grant date and expire on February 3, 2036.
- Following these transactions, Pierce directly beneficially owns 73,334 shares of Common Stock and 15,300 derivative securities (stock options).
- Indirect beneficial ownership includes 712 shares by Son GP, 713 shares by Son AP, and 1,595 shares by 401K.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices that align management incentives with shareholder interests, without indicating any immediate operational or financial shifts.
Positives
- The grants of Restricted Stock Units and employee stock options align the Group President's interests with long-term shareholder value creation.
- These equity awards serve as a significant component of executive compensation, incentivizing retention and performance.
Future Outlook
The equity grants imply a continued long-term commitment from the executive to the company's performance and strategic objectives, with vesting schedules extending several years into the future.
Industry Context
StockSavvy.ai notes that equity grants, such as Restricted Stock Units and stock options, are a standard and widely adopted practice in executive compensation across various industries, including medical technology. This approach is designed to align the financial interests of key management personnel with those of the company's shareholders, fostering a focus on long-term growth and value creation.
Comparison to Industry Standards
- StockSavvy.ai notes that these types of long-term incentive plans are common across the medical technology sector and broader S&P 500 companies, aiming to retain key talent and incentivize performance.
- While specific comparable companies or projects are not detailed in this filing, the structure of multi-year vesting for RSUs and staggered exercisability for options is consistent with best practices in executive compensation, seen in peers like Medtronic (MDT) or Johnson & Johnson (JNJ) for their senior executives.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Plan Reference | The grants were made pursuant to the Stryker 2011 Long-Term Incentive Plan, indicating adherence to established corporate compensation policies. | 02/04/2026 | Reinforces the company's commitment to its existing long-term incentive framework for executive compensation. |
Related Party Transactions
- Indirect beneficial ownership includes shares held by Son GP (712 shares) and Son AP (713 shares), indicating family-related holdings.
Stakeholder Impact
- Shareholders: The equity grants are designed to align the Group President's financial incentives with shareholder value, potentially leading to more focused long-term strategic decisions.
- Employees: While not directly impacting all employees, executive compensation practices can influence overall company culture and perception of fairness in reward systems.
Next Steps
- Vesting of Restricted Stock Units on March 21, 2027, March 21, 2028, and March 21, 2029.
- Employee stock options becoming exercisable annually over five years, starting from February 4, 2027.
Key Dates
| Date | Description |
|---|---|
| 02/04/2026 | Date of grant for Restricted Stock Units and Employee Stock Options. |
| 03/21/2027 | First vesting date for one-third of the granted Restricted Stock Units. |
| 03/21/2028 | Second vesting date for one-third of the granted Restricted Stock Units. |
| 03/21/2029 | Final vesting date for one-third of the granted Restricted Stock Units. |
| 02/03/2036 | Expiration date for the granted Employee Stock Options. |
Recommendation
holdThis Form 4 filing details routine executive compensation grants, which are standard practice for aligning management incentives with shareholder interests. It does not present new information that would significantly alter the fundamental investment thesis for Stryker, hence a 'hold' recommendation is appropriate based solely on this filing.
Keywords
Stryker, SYK, Form 4, Restricted Stock Units, RSU, Stock Options, Equity Compensation, Insider Transaction, Executive Compensation, James Andrew Pierce
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.